20/20 Biolabs gets Nasdaq notice over $2.5 million stockholders’ equity shortfall

• 20/20 Biolabs received Nasdaq notices for failing continued listing standards, raising delisting risk if deficiencies are not cured.
• Nasdaq flagged a sub-$1 bid price over June 3–July 16, 2026; compliance deadline set for Jan. 13, 2027.
• Stock must close at $1 or higher for 10 consecutive sessions to regain compliance within the initial 180-day window.
• Nasdaq also cited stockholders’ equity below the $2.5 million minimum, with equity reported at $1,620,700 in the June 30, 2026 quarter.
• A turnaround plan is due within 45 days; failure to fix equity by Jan. 13, 2027 could block extra time on the bid-price cure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 20/20 Biolabs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-098792), on September 10, 2026, and is solely responsible for the information contained therein.